136 related articles for article (PubMed ID: 37833463)
21. Cancers of the upper aerodigestive tract in Ontario, Canada, and the United States.
Skarsgard DP; Groome PA; Mackillop WJ; Zhou S; Rothwell D; Dixon PF; O'Sullivan B; Hall SF; Holowaty EJ
Cancer; 2000 Apr; 88(7):1728-38. PubMed ID: 10738233
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
[TBL] [Abstract][Full Text] [Related]
23. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head.
Lutfi W; Talamonti MS; Kantor O; Wang CH; Liederbach E; Stocker SJ; Bentrem DJ; Roggin KK; Winchester DJ; Marsh R; Prinz RA; Baker MS
Surgery; 2016 Sep; 160(3):714-24. PubMed ID: 27422328
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry.
Stessin AM; Meyer JE; Sherr DL
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1128-33. PubMed ID: 18538501
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant and neoadjuvant treatment patterns among resectable pancreatic cancer patients in the USA.
Chase M; Friedman HS; Joo S; Navaratnam P
Future Oncol; 2022 Nov; 18(35):3929-3939. PubMed ID: 36520480
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant chemotherapy is associated with improved survival in patients with left-sided pancreatic adenocarcinoma.
Ocuin LM; Hardacre JM; Ammori JB; Rothermel LD; Mohamed A; Selfridge JE; Bajor D; Winter JM
J Surg Oncol; 2020 Dec; 122(8):1595-1603. PubMed ID: 32844445
[TBL] [Abstract][Full Text] [Related]
27. A Propensity Score Analysis of Chemotherapy Use in Patients With Resectable Gallbladder Cancer.
Ozer M; Goksu SY; Sanford NN; Porembka M; Khurshid H; Ahn C; Maxwell MC; Beg MS; Kazmi SM
JAMA Netw Open; 2022 Feb; 5(2):e2146912. PubMed ID: 35171262
[TBL] [Abstract][Full Text] [Related]
28. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery.
Barnes CA; Chavez MI; Tsai S; Aldakkak M; George B; Ritch PS; Dua K; Clarke CN; Tolat P; Hagen C; Hall WA; Erickson BA; Evans DB; Christians KK
Surgery; 2019 Sep; 166(3):277-285. PubMed ID: 31272811
[TBL] [Abstract][Full Text] [Related]
29. Impact of neoadjuvant therapy on postoperative outcomes after pancreaticoduodenectomy.
Cools KS; Sanoff HK; Kim HJ; Yeh JJ; Stitzenberg KB
J Surg Oncol; 2018 Sep; 118(3):455-462. PubMed ID: 30114330
[TBL] [Abstract][Full Text] [Related]
30. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Macedo FI; Ryon E; Maithel SK; Lee RM; Kooby DA; Fields RC; Hawkins WG; Williams G; Maduekwe U; Kim HJ; Ahmad SA; Patel SH; Abbott DE; Schwartz P; Weber SM; Scoggins CR; Martin RCG; Dudeja V; Franceschi D; Livingstone AS; Merchant NB
Ann Surg; 2019 Sep; 270(3):400-413. PubMed ID: 31283563
[TBL] [Abstract][Full Text] [Related]
31. Are Income-based Differences in TKA Use and Outcomes Reduced in a Single-payer System? A Large-database Comparison of the United States and Canada.
Mehta B; Ho K; Ling V; Goodman S; Parks M; Ravi B; Banerjee S; Wang F; Ibrahim S; Cram P
Clin Orthop Relat Res; 2022 Sep; 480(9):1636-1645. PubMed ID: 35543485
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival.
Allendorf JD; Lauerman M; Bill A; DiGiorgi M; Goetz N; Vakiani E; Remotti H; Schrope B; Sherman W; Hall M; Fine RL; Chabot JA
J Gastrointest Surg; 2008 Jan; 12(1):91-100. PubMed ID: 17786524
[TBL] [Abstract][Full Text] [Related]
33. Does the use of neoadjuvant therapy for pancreatic adenocarcinoma increase postoperative morbidity and mortality rates?
Cooper AB; Parmar AD; Riall TS; Hall BL; Katz MH; Aloia TA; Pitt HA
J Gastrointest Surg; 2015 Jan; 19(1):80-6; discussion 86-7. PubMed ID: 25091851
[TBL] [Abstract][Full Text] [Related]
34. Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study.
de Geus SWL; Kasumova GG; Eskander MF; Ng SC; Kent TS; James Moser A; Vahrmeijer AL; Callery MP; Tseng JF
J Gastrointest Surg; 2018 Feb; 22(2):214-225. PubMed ID: 29235000
[TBL] [Abstract][Full Text] [Related]
35. Pancreatic adenocarcinoma: effects of neoadjuvant therapy on post-pancreatectomy outcomes - an American College of Surgeons National Surgical Quality Improvement Program targeted variable review.
Czosnyka NM; Borgert AJ; Smith TJ
HPB (Oxford); 2017 Oct; 19(10):927-932. PubMed ID: 28747265
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.
Wolfe AR; Prabhakar D; Yildiz VO; Cloyd JM; Dillhoff M; Abushahin L; Alexandra Diaz D; Miller ED; Chen W; Frankel WL; Noonan A; Williams TM
Cancer Med; 2020 Jul; 9(13):4711-4723. PubMed ID: 32415696
[TBL] [Abstract][Full Text] [Related]
37. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis.
Shaib WL; Jones JS; Goodman M; Sarmiento JM; Maithel SK; Cardona K; Kane S; Wu C; Alese OB; El-Rayes BF
Oncologist; 2018 Jun; 23(6):704-711. PubMed ID: 29445028
[TBL] [Abstract][Full Text] [Related]
39. Initial treatment is associated with improved survival and end-of-life outcomes for patients with pancreatic cancer: a cohort study.
Khan R; Salim M; Tanuseputro P; Hsu AT; Coburn N; Hallet J; Talarico R; James PD
BMC Cancer; 2022 Dec; 22(1):1312. PubMed ID: 36517794
[TBL] [Abstract][Full Text] [Related]
40. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
